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In this issue a case of CD30+ non-Hodgkin’s lymphoma (NHL)
involving the skin with 
 
en cuirasse
 
 clinical features (large,
indurated, well-defined plaque of the breast, simulating a
carcinoma ‘en cuirasse’) is reported (see pp. 000–000). This
report is definitely worthy of attention for its clinical peculiarity.
On this occasion, however, it seems advisable to stress once
again the usual, distinctive features of primary cutaneous
CD30+ T-cell lymphomas (CD30+ CTCLs), and to discuss the
hypothetical mechanism(s) underlying the most distinctive
clinical feature of this cutaneous lymphoma subtype, i.e. the
spontaneous regression of skin lesions.
CD30+ CTCL represents a well-defined, specific subtype of
NHL with a primary cutaneous presentation.
 
1
 
 Key features
are: the expression of CD30 antigen by neoplastic large cells
at presentation; the possible spontaneous regression of skin
lesions; and the generally favourable clinical course. This dis-
tinctive CTCL subtype includes a spectrum of diseases known
as CD30+ lymphoproliferative disorders of the skin:
 
2,3
 
 primary
cutaneous CD30+ large T-cell lymphoma (CD30+ large cell
CTCL), lymphomatoid papulosis (LyP), and so-called ‘border-
line’ cases. CD30+ large cell CTCL are characterized clinically
by presentation with solitary or localized skin lesions, possible
spontaneous regression (partial to complete), good and rapid
response to local radiotherapy, and favourable prognosis,
despite frequent cutaneous relapses. Histologically, they com-
prise a skin infiltration of large T cells, > 75% of which express
CD30 antigen, regardless of their predominant cytology, i.e.
anaplastic (anaplastic large cell, ALC) or non-anaplastic (pleo-
morphic, immunoblastic).
 
4
 
 LyP, historically defined as ‘a con-
tinuing, self-healing eruption, clinically benign, histologically
malignant’,
 
5
 
 is characterized clinically by an intermittent or
continuous eruption of usually multiple, papulonodular
lesions, with ulceration, crusting and self-healing, sometimes
with scarring and/or depigmentation. Histologically, three
main patterns are recognized (reviewed in Willemze 
 
et al
 
.
 
1
 
):
(i) LyP type A, i.e. large atypical CD30+ cells, scattered or in
small clusters, are interspersed in an extensive inflammatory
infiltrate of histiocytes, small lymphocytes, neutrophils and/or
eosinophils; (ii) LyP type B, i.e. medium-sized cerebriform cells
are arranged in a perivascular to band-like, epidermotropic
infiltrate, simulating classical plaque stage MF; and (iii) LyP
type C, i.e. monotonous infiltration or large clusters of
CD30+ T cells with relatively few admixed inflammatory cells,
resembling CD30+ large cell CTCL. Different histological
types of LyP may occur in different lesions, or part of the
same lesion, of individual patients. ‘Borderline’ cases are
characterized by clinical features typical of large cell lymphoma
with histology of LyP, or vice versa.
 
3
 
Although the functional relevance of CD30 and its natural
ligand (CD30L) expressed in most NHL is presently not known,
previous studies indicate that CD30L is likely to mediate the
reduction of proliferation in CD30+ ALC NHL.
 
6
 
 No informa-
tion was available concerning the expression of CD30L in
primary cutaneous CD30+ lymphomas. We investigated the
immunophenotypic and genotypic expression of CD30
and CD30L in different developmental phases of skin lesions
(growing vs. spontaneously regressing). By immunohistochem-
istry, CD30L expression was detected in regressing lesions
only; by molecular analysis, the expression of CD30L was
clearly higher in regressing lesions than in growing ones.
CD30L, while expressed by some small lymphocytes, was
most often coexpressed by CD30+ neoplastic large cells, as
demonstrated by two-colour immunofluorescence and by
immunohistochemistry on paraffin sections. Taken together,
these data suggest that CD30–CD30L interaction may play
a part in the pathobiology of primary cutaneous CD30+
lymphoproliferative disorders.
 
7
 
 Indeed, CD30L expression
by both neoplastic and reactive cells, possibly enhancing
the tumour cell sensitivity to FasL-mediated cell death might
represent the triggering mechanism for apoptosis, which
is frequent in regressing lesions.
 
8
 
 The lack of activation of
specific oncogenes (low levels of bcl-2 in LyP regressing lesions,
different from CD30+ large cell tumours)
 
9
 
 and the presence of
active receptors for transforming growth factor-
 
b
 
, a potent
growth inhibitor of normal lymphocytes
 
10,11
 
 are possible
prerequisites for the success of the above, putative role of
CD30–CD30L interaction.
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